journal article
LitStream Collection
Looking forward, looking back
2008 Nature Biotechnology
doi: 10.1038/nbt0508-475pmid: 18464754
Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.